Presentation
Innovative Approach for Prognostication in Traumatic Brain Injury - Biomarkers & Endophenotypes
DescriptionSignificant scientific progress in the past two decades has deepened our comprehension of the intricate and diverse pathophysiological mechanisms linked with traumatic brain injury (TBI). Concurrently, numerous experimental therapeutics have exhibited neuroprotective properties in preclinical studies. Regrettably, none of these approaches have demonstrated efficacy in clinical trials for TBI. The failure of clinical therapy trials is often attributed to TBI's heterogeneity, the oversimplified TBI classifications, the lack of biomarkers for therapeutic intervention monitoring, and the limited translatability of preclinical TBI models.
Recognized now is the multifaceted nature of TBI pathophysiology, which involves acute, progressive, and chronic neurodegenerative processes, comprising intricate cascades of biological events at cellular and molecular levels. Corresponding to the diverse pathophysiologic processes in TBI, a range of TBI biofluid-based protein biomarkers and endophenotypes have been identified. These biomarkers encompass axonal injury, dendritic injury, neuronal injury, demyelination, synaptic injury, astroglia injury, and microglia responses. Other plausible links between TBI and long-term outcomes include a combination of: alterations in neurobiological mechanisms and the emergence of other medical comorbidities after injury; and subsequent behavioral and lifestyle changes that put patients at higher risk of poor outcomes.
This talk will provide an update on the current understanding of TBI biofluid-based protein biomarkers, and other emerging post-TBI long-term medical comorbidities and endophenotypes. It will also delve into biomarker evidence in TBI diagnosis, outcome prognosis, and their role as theranostics tools.
Recognized now is the multifaceted nature of TBI pathophysiology, which involves acute, progressive, and chronic neurodegenerative processes, comprising intricate cascades of biological events at cellular and molecular levels. Corresponding to the diverse pathophysiologic processes in TBI, a range of TBI biofluid-based protein biomarkers and endophenotypes have been identified. These biomarkers encompass axonal injury, dendritic injury, neuronal injury, demyelination, synaptic injury, astroglia injury, and microglia responses. Other plausible links between TBI and long-term outcomes include a combination of: alterations in neurobiological mechanisms and the emergence of other medical comorbidities after injury; and subsequent behavioral and lifestyle changes that put patients at higher risk of poor outcomes.
This talk will provide an update on the current understanding of TBI biofluid-based protein biomarkers, and other emerging post-TBI long-term medical comorbidities and endophenotypes. It will also delve into biomarker evidence in TBI diagnosis, outcome prognosis, and their role as theranostics tools.
Event Type
Breakout Session
TimeWednesday, October 16th11:20am - 11:40am PDT
LocationHarbor Ballrooms D-I
Science of Neurocritical Care
Informatics
Nursing Pharmacology
Traumatic Brain Injury
Advanced